Autonomic Nervous System Drugs Practice Questions

Q: Oxybutynin acts by which mechanism?

Muscarinic receptor antagonist. ***Muscarinic receptor antagonist*** - **Oxybutynin** is an **anticholinergic** agent that acts primarily as a competitive antagonist at **muscarinic acetylcholine receptors**, especially M3 receptors in the bladder. - By blocking these receptors, it relaxes the **detrusor muscle**, thereby reducing involuntary contractions and treating symptoms of **overactive bladder**. *Adrenergic receptor antagonist* - Adrenergic receptor antagonists (like **beta-blockers** or **alpha-blockers**) target epinephrine and norepinephrine receptors, which are involved in sympathetic nervous system responses. - These drugs are used for conditions like hypertension or benign prostatic hyperplasia, and their mechanism of action is distinct from oxybutynin's effect on muscarinic receptors. *Histaminic antagonist* - Histaminic antagonists (like **antihistamines**) block histamine receptors and are commonly used to treat allergic reactions or insomnia. - Oxybutynin does not primarily act on histamine receptors, although some anticholinergics can have mild antihistaminic properties. *Serotonergic antagonist* - Serotonergic antagonists block serotonin receptors and are used for conditions such as migraine, nausea, or psychiatric disorders. - Oxybutynin's therapeutic effects are not mediated through antagonism of serotonin receptors.

Q: Advantage of glycopyrrolate over atropine is?

It lacks central nervous system penetration. ***It lacks central nervous system penetration.*** - **Glycopyrrolate** is a **quaternary ammonium compound** and is highly ionized, which prevents it from crossing the **blood-brain barrier**. - This characteristic significantly reduces the risk of **CNS side effects** such as sedation, confusion, or delirium, which are commonly associated with **atropine**. *It is a natural alkaloid* - **Atropine** is a **natural alkaloid** derived from plants like *Atropa belladonna*, whereas **glycopyrrolate** is a synthetic compound. - Being a natural alkaloid does not confer an advantage in terms of selective action or side effect profile. *Can be used in OPC poisoning* - Both **atropine** and **glycopyrrolate** can be used in the treatment of **organophosphate poisoning (OPC)** due to their anticholinergic properties. - However, **atropine** is generally preferred in acute OPC poisoning for its ability to reverse both peripheral and central muscarinic effects. *Is more potent* - While both are **antimuscarinic agents**, their potency can vary depending on the specific receptor subtype or clinical effect. - Glycopyrrolate is often cited for its potent **antisialagogue** (reducing saliva) effect, but atropine is more potent at blocking cardiac vagal effects.

Q: Which among the following is a depolarising muscle relaxant?

Decamethonium. **Correct: Decamethonium** - **Decamethonium** is a **depolarizing neuromuscular blocker** that mimics acetylcholine at the neuromuscular junction, leading to initial muscle fasciculations followed by paralysis. - It binds to and activates **nicotinic acetylcholine receptors**, causing persistent depolarization and preventing further muscle contraction. - While historically important, it is rarely used clinically today compared to succinylcholine. *Incorrect: D-tubocurarine* - **D-tubocurarine** is a **non-depolarizing neuromuscular blocker** that acts as a competitive antagonist at the nicotinic acetylcholine receptors. - It prevents acetylcholine from binding, thereby inhibiting muscle contraction without initial depolarization. *Incorrect: Doxacurium* - **Doxacurium** is a **non-depolarizing neuromuscular blocker** of the long-acting benzylisoquinolinium class. - It functions by competitively blocking acetylcholine at the neuromuscular junction, leading to muscle relaxation. *Incorrect: Atracurium* - **Atracurium** is an **intermediate-acting, non-depolarizing neuromuscular blocker** also of the benzylisoquinolinium class. - It undergoes unique elimination pathways, including **Hofmann elimination** and ester hydrolysis, making it suitable for patients with renal or hepatic impairment.

Q: What is the mechanism of elimination for Atracurium?

Nonenzymatic degradation. ***Nonenzymatic degradation*** - Atracurium is primarily metabolized via **Hofmann elimination**, a **nonenzymatic chemical degradation** process that occurs at physiological pH and temperature, and **ester hydrolysis** by plasma esterases. - This mechanism is advantageous in patients with **renal or hepatic impairment** as its elimination is independent of these organ systems. *Renal excretion* - While some metabolites of atracurium are renally excreted, **renal excretion is not the primary mechanism** of its initial breakdown or elimination. - Drugs primarily eliminated by renal excretion would require dose adjustments in patients with **kidney disease**. *Hepatic elimination* - Atracurium does not depend on the liver for its primary metabolism, making it a suitable choice for patients with **hepatic dysfunction**. - Medications primarily undergoing hepatic elimination, often via **cytochrome P450 enzymes**, would be significantly affected by liver health. *None of the above* - This option is incorrect because nonenzymatic degradation (Hofmann elimination and ester hydrolysis) is a well-established and unique mechanism for atracurium's excretion. - The drug's mechanism of action and metabolism are clearly defined in pharmacology.

Q: Which of the following is a depolarising neuromuscular blocker?

Succinylcholine. ***Succinylcholine*** - **Succinylcholine** works by mimicking acetylcholine and binding to **nicotinic acetylcholine receptors** at the neuromuscular junction, causing initial depolarization and fasciculations, followed by sustained depolarization that prevents further muscle contraction. - Due to its unique mechanism, it is the only clinically used **depolarizing neuromuscular blocker** and is primarily used for rapid sequence intubation because of its fast onset and short duration of action. *Pancuronium* - **Pancuronium** is a **nondepolarizing neuromuscular blocker** that competitively antagonizes acetylcholine receptors at the neuromuscular junction, preventing depolarization without activating the receptors. - It has a slower onset and longer duration of action compared to depolarizing agents, making it unsuitable for rapid intubation. *Dexacurium* - **Dexacurium** is also a **nondepolarizing neuromuscular blocker**, structurally similar to atracurium. - It acts by competitively blocking acetylcholine receptors, leading to muscle relaxation without initial depolarization. *D-Tubocurarine* - **D-Tubocurarine** is an older, prototypical **nondepolarizing neuromuscular blocker** that works by competitively antagonizing acetylcholine receptors. - It is known for its potential to cause **histamine release**, leading to hypotension and bronchospasm, and is now rarely used clinically due to safer alternatives.

Q: What is the drug of choice for the management of hypertension in Phaeochromocytoma?

Phenoxybenzamine (non-selective irreversible alpha blocker). ***Phenoxybenzamine*** - **Phenoxybenzamine** is a **non-selective, irreversible alpha-adrenergic blocker**, making it the drug of choice for managing hypertension in pheochromocytoma. Its **irreversible binding** prevents catecholamines from overstimulating alpha-receptors, ensuring sustained blood pressure control. - Pre-surgical alpha-blockade with phenoxybenzamine is crucial to prevent life-threatening **hypertensive crises** during tumor manipulation, reducing perioperative morbidity and mortality. *Phentolamine (reversible alpha blocker)* - While phentolamine is an **alpha-adrenergic blocker**, it is **reversible** and has a shorter duration of action compared to phenoxybenzamine. - It is typically used for managing **acute hypertensive crises** in pheochromocytoma, but not as the primary long-term preparation or maintenance therapy. *Esmolol (cardioselective beta1 blocker)* - Esmolol is a **beta-blocker** that should only be initiated **after adequate alpha-blockade** has been achieved. If used alone, it can lead to paradoxical hypertension by blocking vasodilator beta-2 receptors, leaving vasoconstrictive alpha-receptors unopposed. - It's mainly used to control **tachycardia** and **arrhythmias** once alpha-blockade is established, not as the initial treatment for hypertension. *Labetalol (combined alpha and beta blocker)* - Labetalol, although a **combined alpha and beta-blocker**, has a **greater beta-blocking effect** than alpha-blocking effect. - Like other beta-blockers, if administered before adequate alpha-blockade, it can precipitate a **hypertensive crisis** due to unopposed alpha-adrenergic stimulation.

Q: Which of the following is a nonselective beta adrenergic antagonist?

Nadolol. ***Nadolol*** - **Nadolol** is well-known for its **non-selective beta-adrenergic blockade**, affecting both beta-1 and beta-2 receptors [1]. - This broad action makes it effective for conditions like **hypertension** and **angina** but can exacerbate conditions like asthma due to beta-2 blockade [1]. *Atenolol* - **Atenolol** is a **beta-1 selective antagonist**, primarily affecting the heart by decreasing heart rate and contractility. - It is often preferred in patients with **respiratory conditions** because it has less impact on bronchial smooth muscle (beta-2 receptors). *Bisoprolol* - **Bisoprolol** is a **highly selective beta-1 blocker** (cardioselective) at low to moderate doses, making it a common choice for heart failure and hypertension. - Its selectivity means it has a **lower risk of bronchospasm** compared to non-selective beta-blockers. *Esmolol* - **Esmolol** is an **ultrashort-acting, cardioselective (beta-1 selective) beta-blocker** administered intravenously [2]. - Its rapid onset and brief duration of action make it suitable for **acute management of supraventricular tachyarrhythmias** and perioperative hypertension [2].

Q: Which of the following does not release histamine?

Pancuronium. ***Pancuronium*** - **Pancuronium** is a **non-depolarizing neuromuscular blocker** that does **not cause histamine release** [1], [2], and therefore has minimal effects on blood pressure and heart rate. - This characteristic makes it a suitable choice for patients where **hemodynamic stability** is crucial. *D- Tubocurarine (D-TC)* - **D-Tubocurarine** is a historical **non-depolarizing neuromuscular blocker** known to cause significant **histamine release** [1], [2]. - Histamine release can lead to **hypotension, bronchospasm**, and other allergic-type reactions [1], [2]. *Succinylcholine* - **Succinylcholine** is a **depolarizing neuromuscular blocker** that can cause **histamine release**, particularly with rapid injection or high doses [1]. - Histamine release can result in **flushing, hypotension**, and **tachycardia**. *Mivacurium* - **Mivacurium** is a **short-acting non-depolarizing neuromuscular blocker** well-known for causing **histamine release** [2]. - The histamine release observed with Mivacurium is often described as **dose-dependent** and can lead to cutaneous flushing and hypotension.

Q: Which cholinergic drug acts on the heart by decreasing the levels of cAMP and opening K+ channels?

Methacholine. ***Methacholine*** - Methacholine is a **muscarinic agonist** that acts on **M2 receptors** in the heart, leading to a decrease in **cAMP** levels and opening of **K+ channels**. - These actions result in **hyperpolarization** of cardiac cells and a reduction in heart rate and contractility. *Oxotremorine* - Oxotremorine is a **non-selective muscarinic agonist** known for its central nervous system effects, often used in research to induce *tremors* and study Parkinson's disease models. - While it activates muscarinic receptors, its primary clinical or pharmacological relevance is not in direct cardiac depression via **cAMP** and **K+ channel** modulation like methacholine. *Bethanechol* - Bethanechol is a **selective muscarinic agonist** primarily acting on the **M3 receptors** in the bladder and gastrointestinal tract, promoting smooth muscle contraction. - It has minimal cardiovascular effects at therapeutic doses and is therefore not the primary agent for cardiac rate and rhythm modulation via **cAMP** and **K+ channels**. *DMPP* - DMPP (**Dimethylphenylpiperazinium**) is a **nicotinic acetylcholine receptor agonist**, known for stimulating **ganglionic nicotinic receptors**. - Its effects are mediated through ganglionic stimulation and not directly by muscarinic receptor activation in the heart that decreases **cAMP** and opens **K+ channels**.

Q: A chronic smoker was on nicotine replacement therapy and clonidine tablets for smoking de-addiction. He stopped taking clonidine tablets and now presents with a headache. What is the reason behind this condition?

Rebound hypertension. ***Rebound hypertension*** - **Clonidine withdrawal** can cause a sudden surge in blood pressure due to increased sympathetic activity, leading to **rebound hypertension** and symptoms like headaches. - This occurs because chronic clonidine use suppresses sympathetic outflow, and its abrupt discontinuation unmasks this suppressed activity, causing a hypertensive crisis. *Postural hypotension* - **Postural hypotension** is a common side effect of clonidine due to its vasodilatory effects, causing blood pressure to drop when standing. - However, the patient's headache following clonidine cessation is more indicative of a **hypertensive event**, not hypotension. *Receptor upregulation* - **Receptor upregulation** refers to an increase in the number of receptors, often in response to prolonged antagonism or decreased ligand exposure. - While receptor changes occur, the primary mechanism of clonidine withdrawal is the **overcompensation** of the sympathetic nervous system, not simply an increased number of receptors. *Receptor hypersensitivity* - **Receptor hypersensitivity** implies an exaggerated response to a normal concentration of a neurotransmitter, which can contribute to withdrawal symptoms. - While it plays a role, the more immediate and critical cause of the headache is the rapid increase in blood pressure due to **rebound sympathetic activity**.

Question 1

Oxybutynin acts by which mechanism?

Accepted Answer

Muscarinic receptor antagonist

Answer

Adrenergic receptor antagonist

Answer

Histaminic antagonist

Answer

Serotonergic antagonist

Question 2

Advantage of glycopyrrolate over atropine is?

Accepted Answer

It lacks central nervous system penetration

Answer

It is a natural alkaloid

Answer

Can be used in OPC poisoning

Answer

Is more potent

Question 3

Which among the following is a depolarising muscle relaxant?

Accepted Answer

Decamethonium

Answer

D-tubocurarine

Answer

Doxacurium

Answer

Atracurium

Question 4

What is the mechanism of elimination for Atracurium?

Accepted Answer

Nonenzymatic degradation

Answer

Renal excretion

Answer

Hepatic elimination

Answer

None of the above

Question 5

Which of the following is a depolarising neuromuscular blocker?

Accepted Answer

Succinylcholine

Answer

Pancuronium

Answer

Dexacurium

Answer

D-Tubocurarine

Question 6

What is the drug of choice for the management of hypertension in Phaeochromocytoma?

Accepted Answer

Phenoxybenzamine (non-selective irreversible alpha blocker)

Answer

Phentolamine (reversible alpha blocker)

Answer

Esmolol (cardioselective beta1 blocker)

Answer

Labetalol (combined alpha and beta blocker)

Question 7

Which of the following is a nonselective beta adrenergic antagonist?

Accepted Answer

Nadolol

Answer

Atenolol

Answer

Bisoprolol

Answer

Esmolol

Question 8

Which of the following does not release histamine?

Accepted Answer

Pancuronium

Answer

d-Tubocurarine

Answer

Succinylcholine

Answer

Mivacurium

Question 9

Which cholinergic drug acts on the heart by decreasing the levels of cAMP and opening K+ channels?

Accepted Answer

Methacholine

Answer

Oxotremorine

Answer

Bethanechol

Answer

DMPP

Question 10

A chronic smoker was on nicotine replacement therapy and clonidine tablets for smoking de-addiction. He stopped taking clonidine tablets and now presents with a headache. What is the reason behind this condition?

Accepted Answer

Rebound hypertension

Answer

Postural hypotension

Answer

Receptor upregulation

Answer

Receptor hypersensitivity

Autonomic Nervous System Drugs — MCQs

Autonomic Nervous System Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?